Cancer drugs from Bristol-Myers Squibb, Novartis, and Roche come with higher price tags than Gilead Sciences hepatitis C drug Harvoni.
Bristol-Myers Squibb was among the best performing pharmaceutical stocks in October, launching 15% higher and tacking on more than $12 billion in market value. Find out what sent Bristol-Myers' shares soaring higher and whether or not it'll continue.
Bristol-Myers Squibb's Opdivo and Merck's Keytruda are sought after drugs for combination cancer treatments.
Johnson & Johnson, Bristol-Myers Squibb, and Pfizer could see sales of their factor Xa drugs Xarelto and Eliquis jump if Portola Pharmaceuticals antidote succeeds in trials.
S&P 500 companies paid out $91.5 billion in dividends last quarter. Unfortunately, not all dividend stocks are created equally. Let's examine two of Big Pharma's highest-yielding stocks to determine which is the better dividend stock.
Sales of Bristol-Myers Squibb and Pfizer's Eliquis are heading higher, threatening Johnson & Johnson's market leadership among factor Xa anticoagulant drugs.
Bristol-Myers Squibb revenue fell by 4% in the second quarter, due mostly to its exit from the diabetes market.
Bristol-Myers Squibb is winning big in Japan, can they bring that success home?
Anacor gets a key pipeline product approved, Bristol-Myers prepares for a landmark new drug filing, and AbbVie continues its never-ending quest to buy Shire.
Let's see what the numbers say about Bristol-Myers Squibb (BMY).